nach oben

Erschienen in:

13.09.2019 | Fettleber | fortbildung

Hepatologie — Teil 5 : Ernährung und NAFLD

Welchen Einfluss haben Ernährung und Genussmittel auf die Fettleber?

verfasst von: Prof. Dr. med. Claus Niederau

Erschienen in: Gastro-News | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Ernährung hat einen entscheidenden Einfluss auf die Entwicklung einer nicht alkoholischen Fettlebererkrankung. Während das Risiko durch hohe Gesamtkalorienzufuhr und erhöhten Kohlenhydratkonsum grundsätzlich steigt, ist die Gefahr durch andere Nahrungs- und Genussmittel aber nicht immer so eindeutig, wie oft vermutet.

Roeb E, Steffen HM, Bantel H, et al. S2k-Leitlinie. Nicht alkoholische Fettlebererkrankung. Z Gastroenterol. 2015; 53: 668–723.PubMedCrossRef

Oddy WH, Herbison CE, Jacoby P, et al. The Western dietary pattern is prospectively associated with nonalcoholic fatty liver disease in adolescence. Am J Gastroenterol. 2013; 108: 778–85.PubMedCrossRef

Chung M, Ma J, Patel K, et al. Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis. Am J Clin Nutr. 2014;100:833–49.PubMedPubMedCentralCrossRef

Chiu S, Sievenpiper JL, de Souza RJ, et al. Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials. Eur J Clin Nutr. 2014;68:416–23.PubMedPubMedCentralCrossRef

Jegatheesan P, De Bandt JP. Fructose and NAFLD: The multifaceted aspects of fructose metabolism. Nutrients. 2017;9. pii: E230.PubMedCrossRef

Jensen T, Abdelmalek MF, Sullivan S, et al. Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. J Hepatol. 2018;65:1063–1075.CrossRef

Dehghan M, Mente A, Zhang X. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. Lancet. 2017;390:2050–2062.PubMedCrossRef

Shi D, Chen J, Wang J, Yao J, Huang Y, Zhang G, Bao Z. Circadian clock genes in the metabolism of Non-alcoholic Fatty Liver Disease. Front Physiol. 2019;10:423PubMedPubMedCentralCrossRef

Kant AK, Graubard BI. Association of self-reported sleep duration with eating behaviors of American adults: NHANES 2005-2010. Am J Clin Nutr. 2014;100:938–47.PubMedPubMedCentralCrossRef

10.

Hunsberger M, Mehlig K, Börnhorst C, et al. Dietary carbohydrate and nocturnal sleep duration in relation to children's BMI: Findings from the IDEFICS study in eight European countries. Nutrients. 2015;7:10223–36.PubMedPubMedCentralCrossRef

11.

Crippa A, Discacciati A, Larsson SC, et al. Coffee consumption and mortality from all causes, cardiovascular disease, and cancer: a dose-response meta-analysis. Am J Epidemiol. 2014;180:763–75.PubMedCrossRef

12.

Zhao Y, Wu K, Zheng J, et al. Association of coffee drinking with all-cause mortality: a systematic review and meta-analysis. Public Health Nutr. 2015;18:1282–91.PubMedCrossRef

13.

Simon TG, Trejo MEP, Zeb I, et al. Coffee consumption is not associated with prevalent subclinical cardiovascular disease (CVD) or the risk of CVD events, in nonalcoholic fatty liver disease: results from the multi-ethnic study of atherosclerosis. Metabolism. 2017;75:1–5.PubMedPubMedCentralCrossRef

14.

Godos J, Micek A, Marranzano M, et al. Coffee consumption and risk of biliary tract cancers and liver cancer: A Dose-Response Meta-Analysis of Prospective Cohort Studies. Nutrients. 2017;9:9.CrossRef

15.

Cardin R, Piciocchi M, Martines D, et al. Effects of coffee consumption in chronic hepatitis C: a randomized controlled trial. Dig Liver Dis. 2013;45:499–504.PubMedCrossRef

16.

Hodge A, Lim S, Goh E, Wong O, et al. Coffee intake is associated with a lower liver stiffness in patients with non-alcoholic fatty liver disease, hepatitis c, and hepatitis B. Nutrients. 2017;9:1.CrossRef

17.

Setiawan VW, Porcel J, Wei P, et al. Coffee drinking and alcoholic and nonalcoholic fatty liver diseases and viral hepatitis in the multiethnic cohort. Clin Gastroenterol Hepatol. 2017;15:1305–7.PubMedPubMedCentralCrossRef

18.

Catalano D, Martines M, Marchesini G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844–50.CrossRef

19.

Shokouh P, Jeppesen PB, Hermansen K, et al. A combination of coffee compounds shows insulin-sensitizing and hepatoprotective effects in a rat model of diet-induced metabolic syndrome. Nutrients. 2017;10:10. pii: E1547CrossRef

20.

Birerdinc A, Stepanova M, Pawloski L, et al. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2012;35:76–82.PubMedCrossRef

21.

Freedman N, Park Y, Abnet C, et al. Association of coffee drinking with total and cause-specific mortality. Engl J Med. 2012;366:1891–904.CrossRef

22.

Gutierrez-Grobe Y, Chavez-Tapia N, Sanchez-Valle V, et al. High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity. Ann Hepatol. 2012;11:350–5.PubMedCrossRef

23.

Molloy J, Calcagno C, Williams C, et al. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology. 2012;55:429–36.PubMedCrossRef

24.

Anty R, Marjoux S, Iannelli A, et al. Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. J Hepatol. 2012;57:1090–6.PubMedCrossRef

25.

Mitchell D, Knight C, Hockenberry J, et al. Beverage caffeine intakes in the U.S. Food Chem Toxicol. 2004;63:136–42.CrossRef

26.

Bambha K, Wilson LA, Unalp A, et al. Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver Int. 2014;34:1250–8.PubMedCrossRef

27.

Graeter T, Niedermayer PC, Mason RA, et al. EMIL-Study group. Coffee consumption and NAFLD: a community based study on 1223 subjects. BMC Res Notes. 2015 3;8:640.CrossRef

28.

Zelber-Sagi S, Salomone F, Webb M, et al. Coffee consumption and nonalcoholic fatty liver onset: A prospective study in the general population. Transl. Res 2015;165:428–36.PubMedCrossRef

29.

Barros RK, Cotrim HP, Daltro C, et al. Nonalcoholic steatohepatitis in morbid obese patients: coffee consumption vs. disease severity. Ann Hepatol. 2016;15:350–5.PubMedCrossRef

30.

Wadhawan M, Anand AC. Coffee and Liver Disease. J Clin Exp Hepatol. 2016;6:40–6.PubMedPubMedCentralCrossRef

31.

Heath RD, Brahmbhatt M, Tahan AC, et al. Coffee: The magical bean for liver diseases. World J Hepatol. 2017;9:689–696.PubMedPubMedCentralCrossRef

32.

Veronese N, Notarnicola M, Cisternino AM, et al. Coffee intake and liver steatosis: A population study in a mediterranean area. Nutrients. 2018;10:1.CrossRef

33.

Wijarnpreecha K, Thongprayoon C, Ungprasert P. Coffee consumption and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29: e8–12.PubMedCrossRef

34.

Shen H, Rodriguez AC, Shiani A, et al. Association between caffeine consumption and nonalcoholic fatty liver disease: a systemic review and meta-analysis. Therap Adv Gastroenterol. 2016;9:113–20.PubMedPubMedCentralCrossRef

35.

Marventano S, Salomone F, Godos J, et al. Coffee and tea consumption in relation with non-alcoholic fatty liver and metabolic syndrome: A systematic review and meta-analysis of observational studies. Clin Nutr. 2016;35:1269–81.PubMedCrossRef

36.

Saab S, Mallam D, Cox GA, et al. Impact of coffee on liver diseases: a systematic review. Liver Int. 2014;34:495–504.PubMedCrossRef

37.

Kennedy OJ, Roderick P, Buchanan R, et al. Systematic review with meta-analysis: coffee consumption and the risk of cirrhosis. Aliment Pharmacol Ther. 2016;43:562–74.PubMedCrossRef

38.

Alferink LJM, Kiefte-de Jong JC, Murad DS. Potential mechanisms underlying the role of coffee in liver health. Semin Liver Dis. 2018;38:193–214.PubMedCrossRef

39.

Salomone F, Li Volti G, Vitaglione P, et al. Coffee enhances the expression of chaperones and antioxidant proteins in rats with nonalcoholic fatty liver disease. Transl Res. 2014;163:593–602.PubMedCrossRef

40.

Watanabe S, Takahashi T, Ogawa H, et al. Daily coffee intake inhibits pancreatic beta cell damage and nonalcoholic steatohepatitis in a mouse model of spontaneous metabolic syndrome, tsumura-suzuki obese diabetic mice. Metab Synd. Relat Disord. 2017;15:170–7.CrossRef

41.

HVS KV, Patel DKS. Biomechanism of chlorogenic acid complex mediated plasma free fatty acid metabolism in rat liver. BMC Complement Altern Med. 2016 5;16:274.

42.

Zheng X, Dai W, Chen X, et al. Caffeine reduces hepatic lipid accumulation through regulation of lipogenesis and ER stress in zebrafish larvae. J Biomed Sci. 2015;22:105.PubMedPubMedCentralCrossRef

43.

Moco S, Martin FP, Rezzi S. Metabolomics view on gut microbiome modulation by polyphenol-rich foods. J Proteome Res. 2012;11:4781–90PubMedCrossRef

44.

Vaughan MJ, Mitchell T, McSpadden, et al. What's inside that seed we brew? A new approach to mining the coffee microbiome. Appl Environ Microbiol. 2015;81:6518–27.PubMedPubMedCentralCrossRef

45.

Nishitsuji K, Watanabe S, Xiao J, et al Effect of coffee or coffee components on gut microbiome and short-chain fatty acids in a mouse model of metabolic syndrome. Sci Rep. 2018;8:16173.PubMedPubMedCentralCrossRef

46.

Zhou L, Foster JA. Psychobiotics and the gut-brain axis: in the pursuit of happiness. Neuropsychiatr Dis Treat. 2015;11:715–23.PubMedPubMedCentral

47.

Tang J, Zheng JS, Fang L, et al. Tea consumption and mortality of all cancers, CVD and all causes: a meta-analysis of eighteen prospective cohort studies. Br J Nutr. 2015;114:673–83.PubMedCrossRef

48.

Zhang C, Qin YY, Wei X, et al. Tea consumption and risk of cardiovascular outcomes and total mortality: a systematic review and meta-analysis of prospective observational studies. Eur J Epidemiol. 2015;30:103–13.PubMedCrossRef

49.

Fon Sing M, Yang WS, Gao S, et al. Epidemiological studies of the association between tea drinking and primary liver cancer: a meta-analysis. Eur J Cancer Prev. 2011;20:157–65.PubMedCrossRef

50.

Mansour-Ghanaei F, Hadi A, Pourmasoumi M, et al. Green tea as a safe alternative approach for nonalcoholic fatty liver treatment: A systematic review and meta-analysis of clinical trials. Phytother Res. 2018;32:1876–84.PubMedCrossRef

51.

Jin X, Zheng RH, Li YM. Green tea consumption and liver disease: a systematic review. Liver Int. 2008;28:990–6.PubMedCrossRef

52.

Hu J, Webster D, Cao J, et al. The safety of green tea and green tea extract consumption in adults - Results of a systematic review. Regul Toxicol Pharmacol. 2018;95:412–33.PubMedCrossRef

53.

Wijarnpreecha K, Thongprayoon C, Edmonds PJ, et al. Associations of sugar- and artificially sweetened soda with nonalcoholic fatty liver disease: a systematic review and meta-analysis. QJM. 2016;109:461–6.PubMedCrossRef

54.

Lohner S, Toews I, Meerpohl JJ. Health outcomes of non-nutritive sweeteners: analysis of the research landscape. Nutr J. 2017;16:55.PubMedPubMedCentralCrossRef

55.

56.

57.

Riveros MJ, Parada A, Pettinelli P. Fructose consumption and its health implications; fructose malabsorption and nonalcoholic fatty liver disease. Nutr Hosp. 2014;29:491–9.PubMed

58.

Buitrago-Lopez A, Sanderson J, Johnson L, et al. Chocolate consumption and cardiometabolic disorders: systematic review and meta-analysis. BMJ. 2011;343:d4488.PubMedPubMedCentralCrossRef

59.

Hooper L, Kay C, Abdelhamid A, et al. Effects of chocolate, cocoa, and flavan-3-ols on cardiovascular health: a systematic review and meta-analysis of randomized trials. Am J Clin Nutr. 2012;95:740–51.PubMedCrossRef

60.

Kerimi A, Williamson G. The cardiovascular benefits of dark chocolate. Vascul Pharmacol. 2015;71:11–5.PubMedCrossRef

61.

Kwok CS, Boekholdt SM, Lentjes MA, et al. Habitual chocolate consumption and risk of cardiovascular disease among healthy men and women. Heart. 2015;101:1279–87.PubMedCrossRef

62.

Strat KM, Rowley TJ, Smithson AT, et al. Mechanisms by which cocoa flavanols improve metabolic syndrome and related disorders. J Nutr Biochem. 2016;35:1–21.PubMedCrossRef

63.

Davison K, Howe PR. Potential implications of dose and diet for the effects of cocoa flavanols on cardiometabolic function. J Agric Food Chem. 2015;63:9942–7.PubMedCrossRef

64.

Malhi H, Loomba R. Editorial: dark chocolate may improve NAFLD and metabolic syndrome by reducing oxidative stress. Aliment Pharmacol Ther. 2016;44:533–4.PubMedPubMedCentralCrossRef

65.

Sander R. Benefits of dark chocolate in treating metabolic syndrome. Nurs Older People. 2012;24:11.PubMed

66.

Dos Santos PR, Ferrari GS, Ferrari CK. Diet, sleep and metabolic syndrome among a legal Amazon population, Brazil. Clin Nutr Res. 2015;4:41–5.PubMedPubMedCentralCrossRef

67.

Loffredo L, Baratta F, Ludovica P, et al. Effects of dark chocolate on endothelial function in patients with non-alcoholic steatohepatitis. Nutr Metab Cardiovasc Dis. 2018;28:143–9.CrossRef

68.

Noad RL, Rooney C, McCall D, et al. Beneficial effect of a polyphenol-rich diet on cardiovascular risk: a randomised control trial. Heart. 2016;102:1371–9.PubMedCrossRef

69.

Leyva-Soto A, Chavez-Santoscoy RA, Lara-Jacobo LR, et al. Daily consumption of chocolate rich in flavonoids decreases cellular genotoxicity and improves biochemical parameters of lipid and glucose metabolism. Molecules. 2018;23. pii: E2220.PubMed

70.

Shah SR, Alweis R, Najim NI, et al. Use of dark chocolate for diabetic patients: a review of the literature and current evidence. J Community Hosp Intern Med Perspect. 2017;7:218–21.PubMedPubMedCentralCrossRef

71.

Carrieri MP, Lions C, Sogni P, et al. Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: results from the ANRS CO13 HEPAVIH cohort study. J Hepatol. 2014;60:46–53.PubMedCrossRef

72.

Alkerwi A, Sauvageot N, Crichton GE, et al. Daily chocolate consumption is inversely associated with insulin resistance and liver enzymes in the Observation of Cardiovascular Risk Factors in Luxembourg study. Br J Nutr. 2016;115:1661–8.PubMedCrossRef

73.

Lee Y, Berryman CE, West SG, et al. Effects of dark chocolate and almonds on cardiovascular risk factors in overweight and obese individuals: a randomized controlled-feeding trial. J Am Heart Assoc. 2017;6 (12). pii:e005162.PubMedPubMedCentral

74.

Tokede OA, Gaziano JM, Djoussé L. Effects of cocoa products/dark chocolate on serum lipids: a meta-analysis. Eur J Clin Nutr. 2011;65:879–86.PubMedCrossRef

75.

Martin FP, Rezzi S, Peré-Trepat E, et al. Metabolic effects of dark chocolate consumption on energy, gut microbiota, and stress-related metabolism in free-living subjects. J Proteome Res. 2009;8:5568–79.PubMedCrossRef

76.

Petyaev IM, Bashmakov YK. Cocobiota: Implications for Human Health. J Nutr Meta. 2016;2016:7906927.

77.

Lv J, Qi L, Yu C, Yang L, et al. China Kadoorie Biobank Collaborative Group. Consumption of spicy foods and total and cause specific mortality: population based cohort study. BMJ. 2015;351:h3942.PubMedPubMedCentralCrossRef

78.

Yuan LJ, Qin Y, Wang L, et al. Capsaicin-containing chili improved postprandial hyperglycemia, hyperinsulinemia, and fasting lipid disorders in women with gestational diabetes mellitus and lowered the incidence of large-for-gestational-age newborns. Clin Nutr. 2016;35:388–93.PubMedCrossRef

79.

Sun F, Xiong S, Zhu Z. Dietary capsaicin protects cardiometabolic organs from dysfunction. Nutrients. 2016;8.

80.

Chopan M, Littenberg B. The association of hot red chili pepper consumption and mortality: a large population-based cohort study. PLoS One. 2017;12:e0169876.PubMedPubMedCentralCrossRef

81.

Sanati S, Razavi BM, Hosseinzadeh H. A review of the effects of Capsicum annuum L. and its constituent, capsaicin, in metabolic syndrome. Iran J Basic Med Sci. 2018;21:439–48.PubMedPubMedCentral

82.

Aune D, Keum N, Giovannucci E. Nut consumption and risk of cardiovascular disease, total cancer, all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis of prospective studies. BMC Med. 2016;14:207.PubMedPubMedCentralCrossRef

83.

Chen GC, Zhang R, Martínez-González MA, et al. Nut consumption in relation to all-cause and cause-specific mortality: a meta-analysis 18 prospective studies. Food Funct. 2017;8:3893–905.PubMedCrossRef

84.

Tuccinardi D, Farr OM, Upadhyay J, et al. Mechanisms Underlying the Cardiometabolic Protective Effect of Walnut Consumption in Obese Subjects: A Cross-Over, Randomized, Double-Blinded, Controlled Inpatient Physiology Study. Diabetes Obes Metab. 2019 May 14.

85.

Kim Y, Keogh J, Clifton PM. Nuts and Cardio-Metabolic Disease: A Review of Meta-Analyses. Nutrients. 2018;10. pii: E1935.PubMedCrossRef

86.

Eslami O, Shidfar F, Dehnad A. Inverse association of long-term nut consumption with weight gain and risk of overweight/obesity: a systematic review. Nutr Res. 2019 Apr 11;68:1–8.PubMedCrossRef

87.

Zhang S, Fu J, Zhang Q, Liu L. Association between nut consumption and nonalcoholic fatty liver disease in adults. Liver Int. 2019. doi: https://doi.org/10.1111/liv.14164.

88.

Dunn W, Sanyal AJ, Brunt EM, et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol. 2012;57:384–91.PubMedPubMedCentralCrossRef

89.

Sookoian S, Castaño GO, Pirola CJ. Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43 175 individuals. Gut. 2014;63:530–2.PubMedCrossRef

90.

GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2018;392:1015–35.PubMedCentralCrossRef

91.

Hagström H. Alcohol Consumption in Concomitant Liver Disease: How Much is Too Much?. Curr Hepatol Rep. 2017;16:152–7.PubMedPubMedCentralCrossRef

92.

Ajmera VH, Terrault NA, Harrison SA. Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review. Hepatology. 2017;65:2090–9.PubMedCrossRef

93.

Liu Y, Dai M, Bi Y, et al. Active smoking, passive smoking, and risk of nonalcoholic fatty liver disease (NAFLD): a population-based study in China. J Epidemiol. 2013;23:115–21.PubMedPubMedCentralCrossRef

94.

Hamabe A, Uto H, Imamura Y, et al. Impact of cigarette smoking on onset of nonalcoholic fatty liver disease over a 10-year period. J Gastroenterol. 2011;46:769–78.PubMedCrossRef

95.

Rezayat AA, Moghadam DM, Nour GM, et al. Association between smoking and non-alcoholic fatty liver disease: A systematic review and meta-analysis. SAGE Open Med. 2018;6:2050312117745223.

96.

Sinha-Hikim AP, Sinha-Hikim I, Friedman TC. Connection of nicotine to diet-induced obesity and non-alcoholic fatty liver disease: cellular and mechanistic insights. Front Endocrinol (Lausanne). 2017 Feb 10;8:23.CrossRef

97.

Andreu V, Mas A, Bruguera M, et al. Ecstasy: a common cause of severe acute hepatotoxicity. J Hepatol. 1998;29:394–7.PubMedCrossRef

98.

Jones AL, Simpson KJ. Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. Aliment Pharmacol. 1999;13:129–33.CrossRef

99.

Tarantino G, Citro V, Finelli C. Recreational drugs: a new health hazard for patients with concomitant chronic liver diseases. J Gastrointest Liver Dis. 2014;23:79–84.

100.

Roy DN, Goswami R. Drugs of abuse and addiction: A slippery slope toward liver injury. Chem Biol Interact. 2016;255:92–105.PubMedCrossRef

101.

Deveaux V, Cadoudal T, Ichigotani Y, et al. Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One. 2009;4:e5844.PubMedPubMedCentralCrossRef

102.

Hézode C, Zafrani ES, Roudot-Horaval F, et al. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology. 2008;134:432–9.PubMedCrossRef

103.

Dibba P, Li A, Cholankeril G, et al. Mechanistic potential and therapeutic implications of cannabinoids in nonalcoholic fatty liver disease. Medicines (Basel). 2018a;5 (2). pii:E47.CrossRef

104.

Dibba P, Li AA, Cholankeril G, et al. The role of cannabinoids in the setting of cirrhosis. Medicines (Basel). 2018b;5 (2). pii:E52CrossRef

Titel: Hepatologie — Teil 5 : Ernährung und NAFLD
Welchen Einfluss haben Ernährung und Genussmittel auf die Fettleber?
verfasst von: Prof. Dr. med. Claus Niederau
Publikationsdatum: 13.09.2019
Verlag: Springer Medizin
Schlagwörter: Fettleber
Ernährung
Capsaicin
Erschienen in: Gastro-News / Ausgabe 5/2019
Print ISSN: 1869-1005
Elektronische ISSN: 2520-8667
DOI: https://doi.org/10.1007/s15036-019-0660-y

Passend zum Thema

Fatal verkannt: Vitamin-B12-Mangel frühzeitig behandeln!

Ernährung

Müdigkeit und Erschöpfung sind meist die ersten Symptome eines Vitamin-B12-Mangels. Wird das Defizit nicht rechtzeitig behandelt, drohen mitunter schwerwiegende Folgen. Lesen Sie hier, was bei der Therapie zu beachten ist.

Vitamin-B12-Mangel durch Arzneimittel

Ernährung

Einige häufig verordnete Medikamente wie das orale Antidiabetikum Metformin oder Protonenpumpeninhibitoren (PPI) können einen Mangel an Vitamin B12 verursachen. Bei einer Langzeitmedikation mit diesen Wirkstoffen sollte daher an ein mögliches Defizit gedacht werden. Erfahren Sie hier, worauf dabei zu achten ist.

Vitamin-B12-Mangel – Aktuelles Basiswissen für die Praxis.

Content Hub

Ein Mangel an Vitamin B12 tritt in bestimmten Risikogruppen häufig auf. Diese Patienten sind auch regelmäßig in Ihrer Praxis. Wird der Mangel nicht rechtzeitig behandelt, drohen mitunter schwerwiegende Folgen. Erhalten Sie hier einen Überblick über aktuelles Basiswissen für den Praxisalltag.

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

Viszeralmedizin 2019 — Interdisziplinär im Mittelpunkt der Medizin

Therapieplanung im interdisziplinären Team grundlegend

Top oder Flop: Was taugt die Unterwasser-Polypektomie mittelgroßer Polypen?

Abtragung großer Polypen: Verhindert der Clip-Verschluss Nachblutungen?

CME: Perianale Fisteln bei Morbus Crohn

Versorgung für Jugendliche mit CED

Passend zum Thema

Fatal verkannt: Vitamin-B12-Mangel frühzeitig behandeln!

Vitamin-B12-Mangel durch Arzneimittel

Vitamin-B12-Mangel – Aktuelles Basiswissen für die Praxis.